About 3,783 results

ALLMedicine™ Narcolepsy Center

Research & Reviews  1,121 results

Metabolomic Signature of Patients With Narcolepsy.
Neurology Yves D, Barateau L et. al.

Dec 1st, 2021 - Narcolepsy type 1 (NT1) is an orphan brain disorder caused by the irreversible destruction of orexin neurons. Metabolic disturbances are common in patients with NT1 who have a body mass index (BMI) 10-20% higher than the general population, with o...

Sleep-Wake Disturbances: Common Side Effect.
Clinical Journal of Oncology Nursing; Mahon SM, Carr E

Nov 21st, 2021 - For sleep-wake disturbances, standards of care are based on established evidence-based practice. Sleep-wake disturbances are defined as ongoing issues with sleep or daytime sleepiness (e.g., circadian rhythm disorder, hypersomnia, insomnia, n...

Comparing objective wakefulness and vigilance tests to on-the-road driving performance ...
Journal of Sleep Research; Bijlenga D, Urbanus B et. al.

Nov 11th, 2021 - Patients with narcolepsy or idiopathic hypersomnia (IH) are at increased risk of driving accidents. Both excessive daytime sleepiness, i.e. unwanted sleep episodes during the day, and disturbed vigilance are core features of these disorders. We te...

Is there any consistent structural and functional brain abnormality in narcolepsy? A me...
Neuroscience and Biobehavioral Reviews; Rahimi-Jafari S, Sarebannejad S et. al.

Nov 11th, 2021 - Is there any consistent structural and functional brain abnormality in narcolepsy? A meta-analytic perspective.|2021|Rahimi-Jafari S,Sarebannejad S,Saberi A,Khazaie H,Camilleri JA,|

see more →

Guidelines  1 results

Practice parameters for the treatment of narcolepsy and other hypersomnias of central o...
Sleep Morgenthaler TI, Kapur VK et. al.

Feb 6th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...

see more →

Drugs  203 results see all →

Clinicaltrials.gov  43 results

Sleep/Wake State Assessment With Non-invasive Earbuds

Oct 21st, 2021 - Detection of "sleepiness" has for more than four decades relied upon methods that acquire the electroencephalogram (EEG) from multiple surface electrodes applied to the scalp and hardware that amplifies and stores information on a central processi...

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Oct 15th, 2021 - The drug being tested in this study is called TAK-994. TAK-994 is being tested in participants with NT1 and NT2. The study will enroll up to approximately 202 participants. The study has 4 Parts: Parts A, B, C (China only) and D. Part A - Part A h...

An Open Label Study of FT218 in Subjects With Narcolepsy

Aug 4th, 2021 - This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (reg...

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Jul 6th, 2021 - This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

Jun 29th, 2021 - Currently, there are insufficient data to guide clinical practice regarding the use of amphetamines for the treatment of narcolepsy. This may be particularly important in the case of narcolepsy type 2, for which randomized, controlled trial data s...

see more →

News  138 results

Stimulant Reduces Apathy in Alzheimer's Disease

Sep 27th, 2021 - Treatment with methylphenidate (Ritalin), a stimulant approved for attention deficit-hyperactivity disorders (ADHD) and narcolepsy, led to a small to medium reduction in apathy in people with Alzheimer's disease, the phase III ADMET 2 trial showed...

COVID-19 mRNA Vaccines: No Serious Health Risks in Large Study

Sep 3rd, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Serious health risks were no more common in the first 3 weeks after Pfizer/BioNTech or Moderna COVID-19 vaccination compared with 22-42 days later...

Neurodegenerative Nature of Schizophrenia Makes Case for LAIs

Aug 27th, 2021 - Schizophrenia is a complex disease caused by dysfunction in specific brain regions or circuits. In fact, schizophrenia is not a single disease but several hundred different diseases, according to Henry A. Nasrallah, MD, who spoke on the topic at a...

FDA Approves First Drug for Idiopathic Hypersomnia

Aug 12th, 2021 - UPDATED with comments August 13, 2032 // The US Food and Drug Administration (FDA) has approved an oral solution of calcium, magnesium, potassium, and sodium oxybates (Xywav) for the treatment of idiopathic hypersomnia in adults, the company annou...

Sparked by Pandemic Fallout, Homeschooling Surges Across US

Jul 26th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Although the pandemic disrupted family life across the U.S. since taking hold in spring 2020, some parents are grateful for one consequence: They'...

see more →

Patient Education  7 results see all →